Articles

Approaches to help build healthcare professional and patient relationships and considerations for symptom management by patients with multiple myeloma are discussed. Read More ›

Healthcare disparities among Black and LGBTQ+ and gender minorities negatively impact clinical outcomes and survivorship. Read More ›

OUTREACH study evaluating liso-cel in patients with R/R LBCL after ≥2 lines of therapy deemed outpatient monitoring feasible with potential cost savings. Read More ›

Results from the OUTREACH study demonstrate that HR-QoL was either improved or maintained from baseline in most patients with R/R LBCL who received liso-cel after ≥2 lines of therapy. Read More ›

Results from the phase 1 study of CTX110 highlighted the potential for immediate “off-the-shelf” availability of CAR-T therapy with demonstrated clinical benefits in R/R LBCL. Read More ›

A real-world analysis of patients with R/R LBCL who experienced relapse or progression following CAR-T therapy found that approximately 20% achieved long-term survival. Read More ›

A multicenter, retrospective analysis evaluating survival outcomes with CAR-T reported median progression-free survival and median overall survival in double-hit and double-expressor lymphomas mirror data reported for patients with DLBCL. Read More ›

Analysis of MTV and clinical outcomes in patients with relapsed or refractory LBCL suggests that MTV is a more accurate and sensitive measure of tumor burden versus sum of product diameters. Read More ›